LBPH - longboardpharma.com Net Margin

Longboard Pharmaceuticals Inc (LBPH) - corporate logo

Longboard Pharmaceuticals (LBPH) net margin ratio reflects market expectations, where a metric value of 0.00 confirms business resilience. This trend is driven by the development of therapies for rare epilepsies, despite global logistical disruptions and patent complexities. Meanwhile, the acquisition by Lundbeck eliminated financial deficits, ensuring the stable completion of final clinical trials.

Longboard (LBPH) - Net Profit Rate from 07/04/2022 to 12/07/2024

Longboard (LBPH) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
- market capitalization statistics:
Basic company analysis:longboardpharma.com - LBPH
Manufactured product of Longboard Pharma

Sales margins serve as an indicator of how effectively revenue is converted into net profit. This metric measures the portion of income remaining after deducting all operating and financial expenses. Analyzing net margin trends allows for the identification of systemic business degradation or rising costs. For Longboard Pharmaceuticals (LBPH), the current decline reflects an R&D stage characterized by fixed investments. Future growth of this indicator is expected following FDA approval through the use of manufacturing outsourcing.

Competitor analysis

BIIB: Net Sales Margin|Net Margin Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Corp) - Net Sales Margin|AXSM: Net Profit Rate|Net Margin acadia-pharm.com (ACAD)|Net Sales Margin Xenon Pharmaceuticals (XENE)|Net Margin Viking Therapeutics VKTX|Net Profit Rate SUPN|CPRX - Net Margin|Net Margin Denali Therapeutics|HRMY: Net Sales Margin|Biohaven - Net Profit Rate|Return on Sales by Net Profit AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Sales Margin|Return on Sales by Net Profit PRAX (Praxis Medicines)|Anavex Corp - Net Return on Sales|Net Margin CeriBell CBLL|Company Sales Margin Prothena Biosciences (PRTA)|ALEC: Return on Sales by Net Profit|ANNX - Net Sales Margin|Omeros Corp. (OMER) - Net Margin|Net Margin Neurogene Inc. (NGNE)|Return on Sales by Net Profit ACIU|Net Margin VYGR|Net Margin Neumora (NMRA)|SCLX - Net Margin|Net Sales Margin TVGN (Tevogen Bio Holdings Inc.)|Net Profit Rate ACOG|Cognition Therapeutics Inc. - Net Sales Margin|IKT - Net Sales Margin|SAVA: Net Sales Margin|Assertio Holdings, Inc. - Net Profit Rate|COYA (Coya) - Net Sales Margin|Net Return on Sales VTGN (Vistagen Therapeutics)|Net Margin Ovid Rx (OVID)|Acumen Pharmaceuticals - Net Return on Sales|Net Margin CervoMed, Inc. CRVO|Net Sales Margin Alterity Therapeutics ATHE|CLNN: Return on Sales by Net Profit|PEPG (pepgen.com) - Net Return on Sales|Jupiter Neurosciences Inc (JUNS) - Net Margin|Relmada Therapeutics - Net Profit Rate|ANVS (Annovis Bio Inc) - Net Sales Margin|GRCE: Net Profit Rate|Net Margin Firefly Neuroscience Inc (AIFF)|KLTO (ANEW Medical) - Net Profit Rate|Net Margin neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Net Margin|MTVA: Return on Sales by Net Profit|NeurAxis, Inc (NRXS) - Return on Sales by Net Profit|HSDT: Net Sales Margin|PASG - Company Sales Margin|Net Margin Neuphoria Therapeutics, Inc.|Net Margin NERV|Net Sales Margin ATHA|ADXN (Addex Therapeutics Ltd) - Net Profit Rate|Net Margin alzamend.com ALZN|Company Sales Margin Cyclerion Therapeutics (CYCN)|Protagenic - Net Sales Margin|Net Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Net Sales Margin|Avenue Therapeutics Inc. (ATXI) - Net Sales Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Net Sales Margin|Net Sales Margin Cara Therapeutics Inc|Net Margin Chromocell Therapeutics (CHRO)|Company Net Profitability ELYM|Net Margin Intra-Cellular ITCI|Net Sales Margin Marinus Pharmaceuticals Inc MRNS|NKGen Biotech Corp - Net Sales Margin|Net Profit Rate NRBO (NeuroBo Pharma)|SAGE (Sage Therapeutics, Inc) - Return on Sales by Net Profit|Net Return on Sales SNPX|Return on Sales by Net Profit TRVN|Net Margin VIGL|Net Sales Margin WENA|Company Sales Margin Cerevel